8 #die in TN after dental procedure. Scientists track down infection to #saline #bottle in dental clinic in #2023. Research by CMC, Vellore ICMR - National Institute of Epidemiology and Directorate of Public Health & Preventive Medicine in The Lancet The Times Of India TOIChennai TOI Health News

An intriguing case report published recently CMC Vellore Clusters of Neuromelioidosis 🧠cases in 2023-A deadly brain infection killed 8 people with potential iatrogenic source linked to single dental clinic after invasive dental procedure using repeated same saline&instruments

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Praveen Kumar Marimuthu: Best of ASCO 2025 – LMIC version Praveen Kumar Marimuthu oncodaily.com/insight/pravee… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #ASCO25 CancerWorld

🧬 The Liquid Biopsy Truth: What $40 Billion in Cancer Screening Really Buys Us A masterful The New Yorker investigation by Siddhartha Mukherjee reveals why finding cancer early isn't what we think it is. Here's what longevity clinics don't tell you... 🧵

Congratulations Praveen Kumar Marimuthu for your eye opening work! Financial distress is a known problem for Indian cancer patients, but it is rarely measured or accounted for in practice or studies. Integrated targeted referrals improving multi- domain distress is encouraging!

📢 IMP work from CMC Vellore (Official) & Adyar Cancer Institute (WIA), Chennai, published in BMJ SPCare. 📈 Timely early palliative care referrals rose from 30–37% ➡️ 60–66% via sustainable QI interventions. 📝 Read doi.org/10.1136/spcare… 👏 Congrats Praveen Kumar Marimuthu, Jewell, JENIFER JEBA SUNDARARAJ Ma’am & the team!

📢 Real-world evidence from Tata Memorial 🇮🇳 In HR+/HER2− metastatic breast cancer, oral chemo-hormonal therapy (capecitabine + hormone therapy) showed encouraging outcomes in a heavily pre-treated cohort (median 3 prior lines): 🧪 Regimens: Capecitabine + • Tamoxifen /

📢Our new paper CMC Vellore (Official) Pathology, MedOnc out in ecancer doi.org/10.3332/ecance… After Dr. Dr Ullas Batra's report, this is largest Indian series of tepotinib-Rxed METex14 mNSCLC. Led by Ashish Singh, Dr. Rekha Pai Anjana Joel, Dr. Rohini Ajoy Oommen John Dr. Deepa Susan #LCSM

🧬 Why doesn’t 5-FU work in dMMR/MSI-H tumors? 👩‍🔬 Normal cells: 5-FU → DNA mismatches ❌ → MMR proteins (MLH1, MSH2, MSH6, PMS2) keep trying to “fix” → futile repair loops → strand breaks → cell death ☠️ 🧟‍♂️ dMMR tumors: 🚫 No proofreader → mismatches go unnoticed → no

Pleased to share our work featuring in this Bloomberg story.. Common Sense Oncology Vinay Prasad MD MPH Bishal Gyawali, MD, PhD, FASCO CMC Vellore bloomberg.com/features/2025-… 🎥 Video Segment: bloomberg.com/news/videos/20… 🔍

Bloomberg Bloomberg (Global, NY) Robert Langreth recently featured our work from CMC Vellore Medical Oncology & Haematology and Tata Memorial Hospital: low-dose immunotherapy and potential for equitable cancer care. What if 1/6th the dose works just as well? bloomberg.com/features/2025-…

Delighted to see this impactful study from CMC Vellore CMC Vellore on low-dose immunotherapy in advanced head and neck cancer gaining broader recognition! Congratulations to Josh Thomas Georgy, Ashish Singh, Ajoy Oommen John and the team back home! nature.com/articles/s4159…

Happy to share our experience... What immunotherapy can achieve in advanced non metastatic HNSCC ? hope this will help our patients in india.. 🇮🇳 ICMR Common Sense Oncology nature.com/articles/s4159…

🚨Out in Scientific Reports Nature Portfolio our study from CMC Vellore Ashish Singh Low-dose nivolumab + induction chemo in unresectable/loc advanced HNSCC led to 75 % ORR, 31 % conversion to resectability, ~90 % cost reduction. See below 🧵on our findings👇nature.com/articles/s4159…

An interesting venue (Cancer Cell!) for this randomized phase 3 trial in #PancreaticCancer. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer cell.com/cancer-cell/fu… Sequential NAT v upfront surgery in resectable PDAC!

🎓 An absolute honour to graduate from the 1st batch of DM Medical Oncology CMC Vellore alongside an exceptional group of colleagues Ajoy Oommen John Josh Thomas Georgy Harikrishna kovilapu Prashant & our ever-inspiring mentor Ashish Singh Grateful & humbled to be a small part of MONC, CMC 🤍💙

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers in ESMO Open. EV shows activity especially in patients with esophageal squamous cell carcinoma, with expected safety profile. esmoopen.com/article/S2059-…